Cereno Scientific AB (publ) Overview
Pro stress-test →Cereno Scientific (NASDAQ First North: CRNO B) is an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases. Its pipeline is led by CS1 and CS014, HDAC inhibitors with disease-modifying potential in PAH and idiopathic pulmonary fibrosis (IPF), respectively, both candidates gearing up for more advanced-stage clinical studies (Phase IIb for CS1 and Phase II for CS014) in H126.
Strategic Profile
Pro stress-test →The strategic focus on rare disease with its clinical portfolio provides a compelling business model characterized by relatively shorter development timelines, reduced capital requirements and the potential for accelerated market entry. The company has collaboration agreements with the University of Michigan for preclinical development and Abbott for use of CardioMEMS HF System.
Competitive Landscape
Pro stress-test →Cereno is well-positioned in an attractive cardiovascular and pulmonary rare disease market with an innovative pipeline, leveraging shorter development timelines and reduced capital requirements typical of rare disease focus. Direct competitors in rare cardiopulmonary indications include biotech companies focused on PAH (Actelion/Johnson & Johnson) and IPF therapeutics (Genentech, Boehringer Ingelheim), though Cereno's epigenetic modulation approach is differentiated.
Industry Context
Cereno Scientific AB (publ) operates in Biotechnology / Rare Disease Therapeutics.
Key facts
Founded: 2012 · Headquarters: Gothenburg, Sweden · Employees: ~10-50 · Revenue: null · Market cap: ≈$195M (SEK 2.1B at ~10.8 SEK/USD)